These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1404 related items for PubMed ID: 9589227

  • 1. The effects of metformin on glycemic control and serum lipids in insulin-treated NIDDM patients with suboptimal metabolic control.
    Robinson AC, Burke J, Robinson S, Johnston DG, Elkeles RS.
    Diabetes Care; 1998 May; 21(5):701-5. PubMed ID: 9589227
    [Abstract] [Full Text] [Related]

  • 2. Acarbose in NIDDM patients with poor control on conventional oral agents. A 24-week placebo-controlled study.
    Lam KS, Tiu SC, Tsang MW, Ip TP, Tam SC.
    Diabetes Care; 1998 Jul; 21(7):1154-8. PubMed ID: 9653611
    [Abstract] [Full Text] [Related]

  • 3. Comparison of insulin with or without continuation of oral hypoglycemic agents in the treatment of secondary failure in NIDDM patients.
    Chow CC, Tsang LW, Sorensen JP, Cockram CS.
    Diabetes Care; 1995 Mar; 18(3):307-14. PubMed ID: 7555472
    [Abstract] [Full Text] [Related]

  • 4. Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients. Troglitazone Study Group.
    Kumar S, Boulton AJ, Beck-Nielsen H, Berthezene F, Muggeo M, Persson B, Spinas GA, Donoghue S, Lettis S, Stewart-Long P.
    Diabetologia; 1996 Jun; 39(6):701-9. PubMed ID: 8781766
    [Abstract] [Full Text] [Related]

  • 5. The effect of a thiazolidinedione drug, troglitazone, on glycemia in patients with type 2 diabetes mellitus poorly controlled with sulfonylurea and metformin. A multicenter, randomized, double-blind, placebo-controlled trial.
    Yale JF, Valiquett TR, Ghazzi MN, Owens-Grillo JK, Whitcomb RW, Foyt HL.
    Ann Intern Med; 2001 May 01; 134(9 Pt 1):737-45. PubMed ID: 11329231
    [Abstract] [Full Text] [Related]

  • 6. Effects of acarbose versus glibenclamide on glycemic excursion and oxidative stress in type 2 diabetic patients inadequately controlled by metformin: a 24-week, randomized, open-label, parallel-group comparison.
    Wang JS, Lin SD, Lee WJ, Su SL, Lee IT, Tu ST, Tseng YH, Lin SY, Sheu WH.
    Clin Ther; 2011 Dec 01; 33(12):1932-42. PubMed ID: 22078152
    [Abstract] [Full Text] [Related]

  • 7. Lipid effects of glyburide/metformin tablets in patients with type 2 diabetes mellitus with poor glycemic control and dyslipidemia in an open-label extension study.
    Dailey GE, Mohideen P, Fiedorek FT.
    Clin Ther; 2002 Sep 01; 24(9):1426-38. PubMed ID: 12380634
    [Abstract] [Full Text] [Related]

  • 8. Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes.
    Moses R, Slobodniuk R, Boyages S, Colagiuri S, Kidson W, Carter J, Donnelly T, Moffitt P, Hopkins H.
    Diabetes Care; 1999 Jan 01; 22(1):119-24. PubMed ID: 10333912
    [Abstract] [Full Text] [Related]

  • 9. Beginning insulin treatment of obese patients with evening 70/30 insulin plus glimepiride versus insulin alone. Glimepiride Combination Group.
    Riddle MC, Schneider J.
    Diabetes Care; 1998 Jul 01; 21(7):1052-7. PubMed ID: 9653594
    [Abstract] [Full Text] [Related]

  • 10. Safety and efficacy of normalizing fasting glucose with bedtime NPH insulin alone in NIDDM.
    Cusi K, Cunningham GR, Comstock JP.
    Diabetes Care; 1995 Jun 01; 18(6):843-51. PubMed ID: 7555511
    [Abstract] [Full Text] [Related]

  • 11. Efficacy of 24-week monotherapy with acarbose, metformin, or placebo in dietary-treated NIDDM patients: the Essen-II Study.
    Hoffmann J, Spengler M.
    Am J Med; 1997 Dec 01; 103(6):483-90. PubMed ID: 9428831
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Impact of metformin versus the prandial insulin secretagogue, repaglinide, on fasting and postprandial glucose and lipid responses in non-obese patients with type 2 diabetes.
    Lund SS, Tarnow L, Frandsen M, Smidt UM, Pedersen O, Parving HH, Vaag AA.
    Eur J Endocrinol; 2008 Jan 01; 158(1):35-46. PubMed ID: 18166815
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Complementary insulin therapy improves blood glucose and serum lipid parameters in type 2 (non-insulin-dependent) diabetic patients. II. Effects on serum lipids, lipoproteins and apoproteins.
    Vaverková H, Chlup R, Ficker L, Novotny D, Bartek J.
    Exp Clin Endocrinol Diabetes; 1997 Jan 01; 105 Suppl 2():74-7. PubMed ID: 9288551
    [Abstract] [Full Text] [Related]

  • 17. Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55-80 years with type 2 diabetes.
    Bode B, Stenlöf K, Harris S, Sullivan D, Fung A, Usiskin K, Meininger G.
    Diabetes Obes Metab; 2015 Mar 01; 17(3):294-303. PubMed ID: 25495720
    [Abstract] [Full Text] [Related]

  • 18. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial.
    Fonseca V, Rosenstock J, Patwardhan R, Salzman A.
    JAMA; 2000 Apr 05; 283(13):1695-702. PubMed ID: 10755495
    [Abstract] [Full Text] [Related]

  • 19. UKPDS 28: a randomized trial of efficacy of early addition of metformin in sulfonylurea-treated type 2 diabetes. U.K. Prospective Diabetes Study Group.
    Diabetes Care; 1998 Jan 05; 21(1):87-92. PubMed ID: 9538975
    [Abstract] [Full Text] [Related]

  • 20. Long-term effects of a sustained-release preparation of acipimox on dyslipidemia and glucose metabolism in non-insulin-dependent diabetes mellitus.
    Davoren PM, Kelly W, Gries FA, Hubinger A, Whately-Smith C, Alberti KG.
    Metabolism; 1998 Mar 05; 47(3):250-6. PubMed ID: 9500558
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 71.